ROME, May 28, 2014 /PRNewswire/ --
Sigma-Tau announces that Synacthen ® (tetracosactide hexa-acetate salt) is now available again in most of the European countries.
Manufacturing challenges connected to tetracosactide over the past months caused the shortage of -Synacthen®- for patients throughout Europe and Sigma-Tau has devoted all its efforts in reestablishing the supply chain into these markets.
Sigma-Tau has already obtained approval for Synacthen® in France, Germany, Austria and The Netherlands and it is confident that the regulatory approvals in the remaining countries, where Sigma-Tau has commercial rights, will follow very soon.
Synacthen® is dedicated to a small population of patients for many diseases such as: neurological disorders ( acute attacks in multiple sclerosis), infantile myoclonic encephalopathy with hypsarrhythmia, rheumatic diseases, skin diseases (pemphigo disease, severe chronic eczema), disorders of the gastrointestinal tract (ulcerative colitis, regional enteritis), and in oncology as an adjuvant to improve the tolerability to chemotherapy.
Press Office - Evolution People
Chiara Gabriele +39 -3403351377 - email@example.com
SOURCE Sigma-Tau Group